ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF Russian patent published in 2016 - IPC C07K16/30 A61K39/395 A61K31/537 A61K47/48 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to immunology and biotechnology. What is described is an immunoconjugate for treating mesothelin-related tumours. The conjugate consists of a human or humanised antibody, or its functional fragment containing an antigen-binding site fused with DM4 cytotoxic agent through SPDB linker. The antibody or its functional fragment show invariant binding to mesothelin, i.e. binding to various tumour cells expressing mesothelin of various forms. The antigen-binding site contains 3 respective light chain CDR-domains and 3 respective heavy chain CDR-domains. There are described a pharmaceutical composition and method of treating mesothelin-related tumours using the immunoconjugate. What is also disclosed is a method for producing the immunoconjugate involving DM4 cytotoxic agent attachment to the antibody through SPDB linker.

EFFECT: using the invention provides the immunoconjugate based on the new antibody able to bind invariantly a mesothelin epitope not cancelled by CA125 that can find application in therapy of tumours.

5 cl, 4 dwg, 3 tbl, 3 ex